Howdy lowed, another point to consider re efti/keytruda combo trials...
So far Merck have kicked in $18M USD as their part in the above US trials....begs the question,
If trials progress positively and PH3 ensues what is Mercks tipping point, i:e when/if does Merck
decide their risk is derisked and their is no need for a collaborative effort any more?.....
note: USD18M is purely supply of keytruda.....
I guess in a nutshell, when /if does Merck think it will be cheaper to take over trials itself rather than wait
for final PH3 where presumably if proven the end result will have gone up immeasurably in value?
Business end. $AU down = Profits Up, page-2
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.020(6.25%) |
Mkt cap ! $435.7M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 31.5¢ | 29.5¢ | $2.355M | 7.796M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 128197 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |